Skip to main content

Postmenopausal Women

2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
EverolimusPhase 2
Best-Link Bioscience
Best-Link BioscienceChina - Shanghai
1 program
1
BL0175Phase 12 trials
Active Trials
NCT07658183Recruiting120Est. May 2028
NCT07366632Not Yet Recruiting27Est. Dec 2026
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
EverolimusPHASE_21 trial
Active Trials
NCT06789900Active Not Recruiting136Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Best-Link BioscienceBL0175
Novo NordiskEverolimus
Best-Link BioscienceBL0175

Clinical Trials (3)

Total enrollment: 283 patients across 3 trials

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

Start: Sep 2026Est. completion: May 2028120 patients
Phase 2Recruiting

Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women

Start: Oct 2024Est. completion: Oct 2026136 patients
Phase 2Active Not Recruiting

A Study of Single Dose of BL0175 in Postmenopausal Women

Start: Jan 2026Est. completion: Dec 202627 patients
Phase 1Not Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 283 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.